PE20220937A1 - Compuestos macrociclicos como agonistas de sting y metodos y usos de los mismos - Google Patents

Compuestos macrociclicos como agonistas de sting y metodos y usos de los mismos

Info

Publication number
PE20220937A1
PE20220937A1 PE2022000120A PE2022000120A PE20220937A1 PE 20220937 A1 PE20220937 A1 PE 20220937A1 PE 2022000120 A PE2022000120 A PE 2022000120A PE 2022000120 A PE2022000120 A PE 2022000120A PE 20220937 A1 PE20220937 A1 PE 20220937A1
Authority
PE
Peru
Prior art keywords
optionally substituted
ring
carboxamido
compound
heteroaryl
Prior art date
Application number
PE2022000120A
Other languages
English (en)
Inventor
Navnath Popat Karche
Moloy Banerjee
Nishant Ramnivasji Gupta
Ganesh Rajaram Jadhav
Vinod Popatrao Vyavahare
Amit Kumar Das
Deepak Sahebrao Walke
Vaibhav Madhukar Kalhapure
Smita Aditya Bhoskar
Vidya Ramdas
Venkata P Palle
Rajender Kumar Kamboj
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of PE20220937A1 publication Critical patent/PE20220937A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
    • C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants

Abstract

La presente invencion se refiere a un compuesto de formula general (I), su forma tautomerica, su estereoisomero, su sal farmaceuticamente aceptable, donde: G1 es -CH2- o -CH(CH2)n-anillo A-; G2 es -CH=CH-; el anillo A es heterociclilo o heteroarilo opcionalmente sustituido; el anillo B es un anillo aromatico; el anillo C es heteroarilo de cinco miembros opcionalmente sustituido; R1 es heteroarilo opcionalmente sustituido, entre otros; R2 es hidrogeno, alquilo C1-C6 opcionalmente sustituido y cicloalquilo C3-C5 monociclico opcionalmente sustituido; o y m son 1; p es 0 a 2. Son compuestos especificos: acido (1S,4S)-4-((E)-12-carbamoil-1,15-bis(1-etil-3-metil-1H-pirazol-5-carboxamido)-8,9,16,19-tetrahidro-7H-6,10-dioxa-2,14,15a,19a-tetraazaciclopentadeca[3,2,1-cd:8,9,10-c'd']diinden-4-carboxamido)ciclohexano-1-carboxilico (Compuesto 1); acido (1R,4R)-4-((E)-12-carbamoil-1,15-bis(1-etil-3-metil-1H-pirazol-5-carboxamido)-8,9,16,19-tetrahidro-7H-6,10-dioxa-2,14,15a,19a-tetraazaciclopentadeca[3,2,1-cd:8,9,10-c'd']diinden-4-carboxamido)ciclohexano-1-carboxilico (Compuesto 2); entre otros. Tambien se refiere a una composicion farmaceutica. Dicho compuesto es un modulador de una proteina estimulador de genes de interferon (STING) y/o un complejo proteico STING, siendo util en el tratamiento del cancer y enfermedades infecciosas.
PE2022000120A 2019-07-22 2020-07-22 Compuestos macrociclicos como agonistas de sting y metodos y usos de los mismos PE20220937A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN201921029556 2019-07-22
IN201921051086 2019-12-10
IN202021003961 2020-01-29
PCT/IB2020/056875 WO2021014365A1 (en) 2019-07-22 2020-07-22 Macrocyclic compounds as sting agonists and methods and uses thereof

Publications (1)

Publication Number Publication Date
PE20220937A1 true PE20220937A1 (es) 2022-05-31

Family

ID=72422197

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022000120A PE20220937A1 (es) 2019-07-22 2020-07-22 Compuestos macrociclicos como agonistas de sting y metodos y usos de los mismos

Country Status (17)

Country Link
US (1) US20220289763A1 (es)
EP (1) EP4004002A1 (es)
JP (1) JP2022541330A (es)
KR (1) KR20220035955A (es)
CN (1) CN114174303A (es)
AU (1) AU2020319058A1 (es)
BR (1) BR112022001125A2 (es)
CA (1) CA3147397A1 (es)
CL (1) CL2022000145A1 (es)
CO (1) CO2022001814A2 (es)
CR (1) CR20220029A (es)
EC (1) ECSP22005485A (es)
IL (1) IL289740A (es)
MX (1) MX2022000939A (es)
PE (1) PE20220937A1 (es)
WO (1) WO2021014365A1 (es)
ZA (1) ZA202201375B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11155567B2 (en) 2019-08-02 2021-10-26 Mersana Therapeutics, Inc. Sting agonist compounds and methods of use
WO2021206158A1 (ja) 2020-04-10 2021-10-14 小野薬品工業株式会社 がん治療方法
EP4277904A1 (en) * 2021-01-15 2023-11-22 Seagen Inc. Immunomodulatory antibody-drug conjugates
UY39705A (es) * 2021-03-30 2022-10-31 Jacobio Pharmaceuticals Co Ltd Novedosos compuestos útiles como agonistas de sting y sus usos

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20010395A1 (it) 2001-02-27 2002-08-27 Dompe Spa Omega-amminoalchilammidi di acidi r-2-aril-propionici come inibitori della chemiotassi di cellule polimorfonucleate e mononucleate
AR046959A1 (es) 2003-12-18 2006-01-04 Tibotec Pharm Ltd Morfolinilo que contiene bencimidazoles como inhibidores de la replicacion del virus sincitial respiratorio
US7488736B2 (en) 2004-05-17 2009-02-10 Epix Delaware, Inc. Thienopyridinone compounds and methods of treatment
NZ567140A (en) 2005-10-07 2011-09-30 Exelixis Inc Azetidines as MEK inhibitors for the treatment of proliferative diseases
CN101506175A (zh) 2006-06-15 2009-08-12 贝林格尔·英格海姆国际有限公司 作为蛋白激酶C-α抑制剂的2-苯氨基-4-（杂环基）氨基-嘧啶
WO2008090570A1 (en) 2007-01-25 2008-07-31 Panacea Biotec Ltd Novel antimicrobials
TW201000447A (en) 2008-05-30 2010-01-01 Astrazeneca Ab New compounds useful in pain therapy
WO2011091446A1 (en) * 2010-01-22 2011-07-28 Glaxosmithkline Llc Chemical compounds
WO2012083053A2 (en) * 2010-12-15 2012-06-21 Abbott Laboratories Anti-viral compounds
AU2013366974B2 (en) 2012-12-28 2017-11-02 Nippon Zoki Pharmaceutical Co., Ltd. Cinnamic acid amide derivative
ES2692226T3 (es) * 2014-06-04 2018-11-30 Glaxosmithkline Intellectual Property Development Limited Dinucleótidos cíclicos como moduladores de STING
US20180147187A1 (en) 2015-01-12 2018-05-31 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
WO2017011920A1 (en) 2015-07-22 2017-01-26 The Royal Institution For The Advancement Of Learning/Mcgill University Compounds and uses thereof in the treatment of cancers and other medical conditions
US10981901B1 (en) * 2016-04-07 2021-04-20 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides useful as protein modulators
AU2017247806B2 (en) 2016-04-07 2019-11-14 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides useful as protein modulators
CN109153678B (zh) 2016-05-27 2020-04-14 石药集团中奇制药技术（石家庄）有限公司 作为fgfr4抑制剂的杂环化合物
EA037671B1 (ru) * 2017-02-22 2021-04-29 Глэксосмитклайн Интеллекчуал Проперти Девелопмент Лимитед Гетероциклические амиды, пригодные в качестве модуляторов белков
JP2020524717A (ja) 2017-06-22 2020-08-20 キュラデブ・ファーマ・リミテッドＣｕｒａｄｅｖ Ｐｈａｒｍａ Ｌｉｍｉｔｅｄ ヒトｓｔｉｎｇの小分子調節因子
JP2020524718A (ja) 2017-06-22 2020-08-20 キュラデブ・ファーマ・リミテッドＣｕｒａｄｅｖ Ｐｈａｒｍａ Ｌｉｍｉｔｅｄ ヒトｓｔｉｎｇの複素環式小分子調節因子
AU2018288018C1 (en) 2017-06-22 2022-10-20 Curadev Pharma Limited Small molecule modulators of human STING
CN111615388B (zh) 2017-07-27 2023-11-14 斯汀格瑞治疗股份有限公司 癌症免疫治疗剂
WO2019027857A1 (en) 2017-08-04 2019-02-07 Merck Sharp & Dohme Corp. COMBINATIONS OF PD-1 ANTAGONISTS AND STING BENZO [B] THIOPHENIC AGONISTS FOR THE TREATMENT OF CANCER
EP3661498A4 (en) 2017-08-04 2021-04-21 Merck Sharp & Dohme Corp. BENZO [B] THIOPHEN STING ANTAGONISTS FOR CANCER TREATMENT
US11377440B2 (en) * 2017-10-05 2022-07-05 Glaxosmithkline Intellectual Property Development Limited Modulators of stimulator of interferon genes (STING)
TW201927771A (zh) * 2017-10-05 2019-07-16 英商葛蘭素史密斯克藍智慧財產發展有限公司 可作為蛋白質調節劑之雜環醯胺及其使用方法
WO2020132582A1 (en) * 2018-12-21 2020-06-25 Nimbus Titan, Inc. Sting agonists and uses thereof
EP3946610A1 (en) * 2019-03-28 2022-02-09 Lupin Limited Macrocyclic compounds as sting agonists

Also Published As

Publication number Publication date
CL2022000145A1 (es) 2022-09-09
CO2022001814A2 (es) 2022-04-29
ZA202201375B (en) 2022-09-28
MX2022000939A (es) 2022-04-06
US20220289763A1 (en) 2022-09-15
AU2020319058A1 (en) 2022-02-17
KR20220035955A (ko) 2022-03-22
JP2022541330A (ja) 2022-09-22
CN114174303A (zh) 2022-03-11
IL289740A (en) 2022-03-01
ECSP22005485A (es) 2022-02-25
CR20220029A (es) 2022-03-14
WO2021014365A1 (en) 2021-01-28
BR112022001125A2 (pt) 2022-03-15
CA3147397A1 (en) 2021-01-28
EP4004002A1 (en) 2022-06-01

Similar Documents

Publication Publication Date Title
PE20220937A1 (es) Compuestos macrociclicos como agonistas de sting y metodos y usos de los mismos
PE20230249A1 (es) Compuestos de heteroarilo biciclicos y usos de estos
MX2022008066A (es) Compuestos triciclicos sustituidos.
MX2022006475A (es) Compuestos triciclicos sustituidos.
ES2257062T3 (es) Derivados de artemisinina antiparasitarios (endoperoxidos).
CR20200588A (es) Compuestos novedosos
PE20190705A1 (es) COMPUESTOS DE BENZO[b] TIOFENO COMO AGONISTAS DE STING
CL2017001932A1 (es) Dinucleotidos cíclicos útiles para el tratamiento de cancer entre otros.
EA201992601A1 (ru) Конденсированное имидазопиперидиновое соединение, являющееся ингибитором jak
CO2019011873A2 (es) Compuestos de heteroarilo bicíclicos 6–6 fusionados y su uso como inhibidores de lats
BR112014009306B1 (pt) Compostos de (hetero)aril ciclopropilamina como inibidores de lsd1
PE20141824A1 (es) Compuestos terapeuticamente activos y sus metodos de uso
EA201991316A1 (ru) Конъюгаты, содержащие двойной агонист glp-1/глюкагона, линкер и гиалуроновую кислоту
KR20140081883A (ko) Lsd1 억제제로서의 (헤테로)아릴 사이클로프로필아민 화합물
EA201001595A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
AR066972A1 (es) Derivados azapeptidicos
JO2787B1 (en) Alternative amide derivatives and methods of use
EA200600811A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ ТЕТРАГИДРОСПИРО {ПИПЕРИДИН-2,7'-ПИРРОЛО [3,2-b]ПИРИДИНА} И НОВЫЕ ПРОИЗВОДНЫЕ ИНДОЛА, ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ РАССТРОЙСТВ, СВЯЗАННЫХ С 5-HT-РЕЦЕПТОРОМ
EA200500286A1 (ru) Новые изотиазольные и изоксазольные соединения в качестве ингибиторов трансформирующего фактора роста (тфр)
EA201070929A1 (ru) ФУРО- И ТИЕНО[3,2-c]ПИРИДИНЫ
EA201500050A1 (ru) Бифтордиоксалан-амино-бензимидазольные ингибиторы киназы для лечения рака, аутоиммунного воспаления и нарушений цнс
CO2022002804A2 (es) Piperidinil-metil-purinaminas como inhibidores de nsd2 y antineoplásicos
AR050914A1 (es) Agonista receptor de vasopresina peptidico
UY33473A (es) Compuestos y métodos para el tratamiento o la prevencion de infecciones por flavivirus
PE20220169A1 (es) Compuestos macrociclicos como agonistas de sting